New test could spot deadly drug side effects before they strike brain cancer patients
NCT ID NCT07406230
Summary
This study aims to develop a better way to monitor patients with a rare brain cancer (primary central nervous system lymphoma) who are receiving a key chemotherapy drug called methotrexate. The drug can cause serious kidney damage, which can delay further life-saving treatments. Researchers will test if taking early blood samples can predict which patients are at risk for this kidney damage, allowing doctors to give a rescue medication sooner to protect the kidneys.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Assistance Publique - Hôpitaux de Marseille
Marseille, 13005, France
Contact
Contact
Conditions
Explore the condition pages connected to this study.